Navigation Links
Promising Parkinson's Disease Research Highlighted by The Michael J. Fox Foundation to Accelerate Drug Development
Date:7/11/2013

ased therapeutic potential as it targets both early amyloid assemblies as well as pre-existing aggregates.

Symptomatic Research

  • Cynapsus Therapeutics' development of APL-130277, a novel formulation of the drug apomorphine, as a rescue medication for intermittent OFF episodes in PD. APL-130277 is a thin film strip that dissolves under the tongue.
  • NeuroDerm's clinical research on continuous administration of levodopa and carbidopa through a "pump-patch." This technology could maintain continuous and constant concentration of levodopa in the blood, which should significantly decrease motor fluctuations and possibly reverse dyskinesia.

To date, the Foundation has funded $325 million in research, more than $84 million of which has been directed to over 185 unique projects led by industry partners.

For more information on the MJFF Partnering Program 1H 2013 participants and previously featured grantees, visit https://www.michaeljfox.org/research/opportunities-for-industry/partnering-program.html. The MJFF Research Partnerships team can be reached at ResearchPartnerships@michaeljfox.org.


'/>"/>
SOURCE The Michael J. Fox Foundation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Adult and Adolescent Vaccines Market to 2018 Report - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth
2. QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion Diagnostics
3. Novan Announces Promising Results of SB204 Clinical Study
4. International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma
5. Use Of Cryoablation For Treatment Of Breast Cancer Shows Promising Results
6. Statement from the Cystic Fibrosis Foundation on Promising Phase 2 Clinical Trial Results of Kalydeco and VX-661 (Vertex Pharmaceuticals Inc.)
7. University of Michigans Zell Lurie Institute Awards $112,000 to Promising Student Startups in 30th Annual Business Plan Competition and Dare to Dream Grant Program
8. Forbes Ranks SynCardia Among "Americas Most Promising Companies" for Second Straight Year
9. Meth Vaccine Shows Promising Results in Early Tests
10. Epigenetics R&D Pipeline - Histone Deacetylases (HDACs) Offer the Most Promising Targets and Outnumber Other Classes of Epigenetic Targets
11. Boston Scientific Announces Promising Clinical Data on New Products at the International Spine Intervention Society 20th Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 2014 The Female Health Company (NASDAQ-CM: FHCO), ... call to discuss its operating results for the fourth ... Tuesday, December 2, 2014 at 11:00 a.m. Eastern Standard ... results earlier the same day. Shareholders and ... by dialing 1-877-374-8416 (international participants dial 1-412-317-6716) and asking ...
(Date:11/24/2014)... , 24 novembre 2014  Surgical Theater ... tecnologia sarà esposta durante l,apertura in data ... d,Europa, ossia la Fondazione IRCCS Istituto Neurologico ... Planner (SRP) (strumento di pianificazione chirurgica) e ... navigazione chirurgica avanzata) saranno presentati in occasione ...
(Date:11/22/2014)... 2014  Sprout Pharmaceuticals today announced positive preliminary results from ... with flibanserin up to 200 mg at bedtime had no ... the 20 th Annual Fall Scientific Meeting of the ... in Miami . The Phase ... Response Letter and the Formal Dispute Resolution that was filed ...
Breaking Medicine Technology:The Female Health Company To Report FY2014 Operating Results on Tuesday, December 2, 2014 2La tecnologia di Surgical Theater in mostra in Italia all'apertura del centro Besta NeuroSim di Milano 2La tecnologia di Surgical Theater in mostra in Italia all'apertura del centro Besta NeuroSim di Milano 3La tecnologia di Surgical Theater in mostra in Italia all'apertura del centro Besta NeuroSim di Milano 4Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 2Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 3
... export sectors -- HONG KONG, Oct. 26 /PRNewswire-Asia/ -- ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
... (Nasdaq: ROCM ) will announce quarterly results after ... will then hold a quarterly conference call to discuss its ... time (4:30 p.m. eastern time). This call is ... Medical,s website at www.rocm.com .  To listen live to ...
Cached Medicine Technology:Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 2Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 3Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 4Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 5Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 6Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 7Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 8Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 9Rochester Medical Announces Fourth Quarter 2010 Earnings Conference Call Thursday, November 4, 2010 2
(Date:11/24/2014)... Houston, TX (PRWEB) November 24, 2014 ... in all of the wrong ingredients. Consistently consuming a ... body to develop stores of excess fat that typically ... health problems and rearing its ugly head in the ... , When dieters make the decision to rid ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 ReAdmission ... and disease management services to health plans, hospitals, ... Essette’s Medical Management software suite. ReAdmission Solutions ... in a program to reduce patients' avoidable readmissions ... Health Management, Care Management, Utilization Management, and Appeals ...
(Date:11/24/2014)... Diego, California (PRWEB) November 24, 2014 Dr. ... San Diego Fertility Center, recently appeared on NBC to discuss ... option. Egg freezing has been trending in the news recently, ... this expensive procedure for women. , “[The companies] ... women who are on a career hot path.” Says Dr. ...
(Date:11/23/2014)... November 24, 2014 The clinical ... 2014" provides data on the Aspergillosis clinical trial ... relating to the clinical trials on Aspergillosis. It ... their recruitment status as per the site of ... a preliminary coverage of disease clinical trials by ...
(Date:11/23/2014)... 24, 2014 For the coming special ... has launched a great promotion for many products, especially ... can get the best choice with amazing discounts, up ... Tidebuy.com. , It is easy to buy colored ... that, this selection is also famous for delicate craftsmanship, ...
Breaking Medicine News(10 mins):Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 2Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 3Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 4Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Beautiful Wedding Dresses Available at Popular B2C Company Tidebuy 2
... now infarct size has only been measured as part of ... being that the reference method of gadolinium based contrast agents ... to perform, and can only be undertaken by imaging specialists," ... Padua, Italy. "The advantages of STE over MRI is that ...
... HealthDay Reporter , TUESDAY, Dec. 6 (HealthDay News) -- Working ... may also increase your risk of developing type 2 diabetes, new ... found that those who worked rotating night shifts were more likely ... the longer that they worked a rotating shift schedule, the greater ...
... TX - Accelerated partial breast irradiation (APBI) brachytherapy, ... popular as a treatment choice for women with ... of later mastectomy, increased radiation-related toxicities and post-operative ... according to researchers from The University of Texas ...
... Denise Mann HealthDay Reporter , TUESDAY, Dec. 6 ... for preterm birth as early as 23 weeks during their ... reduce the baby,s risk of serious developmental issues, including brain ... the Dec. 7 issue of the Journal of the ...
... , TUESDAY, Dec. 6 (HealthDay News) -- U.S. ... remove controversial, unapproved and illegally labeled HCG weight loss products ... a hormone made by the human placenta and found in ... in conjunction with an extremely low-calorie diet -- as low ...
... Reinberg HealthDay Reporter , TUESDAY, Dec. 6 (HealthDay ... with hormone therapy do not appear to be at increased ... new review of evidence. Hormone therapy called "androgen ... previous studies found that the therapy might increase the risk ...
Cached Medicine News:Health News:Echocardiography offers the future for infarct size quantification 2Health News:Echocardiography offers the future for infarct size quantification 3Health News:Echocardiography offers the future for infarct size quantification 4Health News:Rotating Shift Work May Boost Women's Diabetes Risk 2Health News:Rotating Shift Work May Boost Women's Diabetes Risk 3Health News:Study finds side effects, complications, mastectomy more likely after partial breast irradiation 2Health News:Study finds side effects, complications, mastectomy more likely after partial breast irradiation 3Health News:Steroids May Boost Survival for Very Preemie Babies 2Health News:FDA Targets Homeopathic Weight Loss Products 2Health News:FDA Targets Homeopathic Weight Loss Products 3Health News:FDA Targets Homeopathic Weight Loss Products 4Health News:Hormone Drugs Might Not Raise Heart-Related Deaths in Prostate Patients 2Health News:Hormone Drugs Might Not Raise Heart-Related Deaths in Prostate Patients 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: